Metformin Alleviates Sepsis-Associated Myocardial Injury by Enhancing AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Signaling Pathway–Mediated Autophagy
- 1 October 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 82 (4) , 308-317
Abstract
Sepsis-associated myocardial injury is one of the main causes of death in intensive care units, and current clinical treatments have not been satisfactory. Therefore, finding an effective intervention is an urgent requirement. Metformin, an anti–type 2 diabetes drug, has been reported to be an autophagic activator agent that confers protection in some diseases. However, it is unclear whether it can provide defense against sepsis-associated myocardial injury. In this study, we investigated the cardioprotective effects of metformin pretreatment against lipopolysaccharide (LPS)-induced myocardial injury in C57BL/6J mice or H9c2 cells and the possible underlying mechanisms. Metformin was administered at a dose of 100 mg/kg for a week before LPS intraperitoneal injection. Twenty-four hours after LPS intervention, echocardiographic evaluation, reactive oxygen species measurement, Hoechst staining, western blotting, hematoxylin and eosin staining, and enzyme-linked immunosorbent assay were performed. Inhibitors of autophagy and AMP-activated protein kinase (AMPK) were used to further clarify the mechanisms involved. Metformin pretreatment effectively attenuated cardiac dysfunction, reduced the levels of myocardial enzymes, and alleviated cardiac hydroncus in LPS-treated mice. In addition, metformin restored the LPS-disrupted antioxidant defense and activated LPS-reduced autophagy by modulating the AMPK/mammalian target of rapamycin (AMPK/mTOR) pathway both in vivo and in vitro. The antioxidant effects of metformin on cardiomyocytes were abolished by the autophagy inhibitor 3-methyladenine (3-MA). Treatment with compound C, an AMPK inhibitor, reversed the metformin-induced autophagy in LPS-treated H9c2 cells. In conclusion, metformin pretreatment alleviates LPS-induced myocardial injury by activating AMPK/mTOR pathway–mediated autophagy.Keywords
Funding Information
- National College Students Innovation and Entrepreneurship Training Program (20210114026)
- Natural Science Foundation of Shanxi Province (201801D121332)
- Scholarship Council Foundation of Shanxi Provincial Human Resources and Security Department (20220039)
- Scholarship Council Foundation of Shanxi Provincial Education Department (2022-187)
This publication has 37 references indexed in Scilit:
- New Insights into the Role of Mitochondrial Dynamics and Autophagy during Oxidative Stress and Aging in the HeartOxidative Medicine and Cellular Longevity, 2014
- Autophagy in Human Health and DiseaseNew England Journal of Medicine, 2013
- NOX1/NADPH oxidase is involved in endotoxin-induced cardiomyocyte apoptosisFree Radical Biology and Medicine, 2012
- AMP-activated protein kinase: nature's energy sensorNature Chemical Biology, 2011
- AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1Nature Cell Biology, 2011
- Cardioprotection, attenuated systemic inflammation, and survival benefit of β1-adrenoceptor blockade in severe sepsis in rats*Critical Care Medicine, 2010
- Metformin Prevents Progression of Heart Failure in DogsCirculation, 2009
- Activation of AMP-Activated Protein Kinase by Metformin Improves Left Ventricular Function and Survival in Heart FailureCirculation Research, 2009
- LPS-induced autophagy is mediated by oxidative signaling in cardiomyocytes and is associated with cytoprotectionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Mitochondrial Respiratory Complex I Regulates Neutrophil Activation and Severity of Lung InjuryAmerican Journal of Respiratory and Critical Care Medicine, 2008